Stock MAAT MAAT PHARMA
Add to a list
To use this feature you must be a member
Log inSign up

MaaT Pharma Share Price

Equities

MAAT

FR0012634822

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 13:05:14 26/04/2024 BST 		5-day change 1st Jan Change
9.06 EUR 0.00% Intraday chart for MaaT Pharma +3.90% +29.80%
04-15 MaaT Pharma: positive data in graft-versus-host disease CF
04-15 MaaT Pharma Presents Positive 18-Month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event CI

Financials

Sales 2024 * 4M 4.28M 342M Sales 2025 * 4.4M 4.7M 377M Capitalization 105M 112M 9B
Net income 2024 * -29M -31.01M -2.48B Net income 2025 * -29M -31.01M -2.48B EV / Sales 2024 * 31.9 x
Net Debt 2024 * 22.5M 24.06M 1.93B Net Debt 2025 * 53.7M 57.42M 4.6B EV / Sales 2025 * 36.1 x
P/E ratio 2024 *
-3.55 x
P/E ratio 2025 *
-3.52 x
Employees 56
Yield 2024 *
-
Yield 2025 *
-
Free-Float 55.48%
More Fundamentals * Assessed data

Chart MaaT Pharma

Dynamic Chart

Latest news about MaaT Pharma

MaaT Pharma: positive data in graft-versus-host disease CF
MaaT Pharma Presents Positive 18-Month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event CI
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming to Improve Patients? Responses to Immunotherapies CI
MaaT Pharma SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
MaaT Pharma Names Chief Business Officer MT
Maat Pharma SA Appoint Jonathan Chriqui as Chief Business Officer CI
MaaT Pharma: Phase 2 trial recruitment completed CF
Maat Pharma Indicates Completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial Evaluating Maat013 in Combination with Immune Checkpoint Inhibitors in Metastatic Melanoma CI
Transcript : MaaT Pharma SA - Special Call
MaaT Pharma: positive results in blood cancers CF
MaaT Pharma to Receive EUR7 Million Government Funding for Blood Cancer Therapy Study MT
MaaT Pharma SA Announces Its Ongoing Phase 2B Trial, Called Phoebus, Aimed At Evaluating MaaT033 to Improve Overall Survival for Patients Receiving allo-HSCT2 CI
Fragmented feeling? Our Logo
MaaT Pharma Begins Mid-stage Study for MaaT033 Capsule MT
MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT CI
More news

Latest transcript on MaaT Pharma

Logo MaaT Pharma
MaaT Pharma SA - Special Call
More transcripts

Analyst Recommendations on MaaT Pharma

Fragmented feeling? Our Logo
But where have the bears gone? Our Logo
MaaT Pharma's Immune Disorder Therapy Shows Improved Survival Rate In Clinical Trials MT
More recommendations

Press releases MaaT Pharma

MaaT Pharma to Hold Annual General Meeting on May 28, 2024 BU
Long-term data indicates "significant" potential of aGvHD microbiome treatment AQ
MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event BU
Advancing microbiome innovation AQ
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies BU
More press releases

News in other languages on MaaT Pharma

MaaT Pharma annonce la tenue de son Assemblée Générale Mixte le 28 mai 2024
MaaT Pharma : données positives dans la maladie du greffon
Bolsa de Madrid: ¿Vuelve a subir todo?
Est-ce que tout augmente à nouveau ?
En Direct des Marchés : BNP Paribas, Vinci, Dassault, Salesforce, Apple, Prysmian, Nike...
More news

Quotes and Performance

1 week+3.90%
Current month+2.95%
1 month-2.79%
3 months+26.54%
6 months+33.24%
Current year+29.80%
More quotes

Highs and lows

1 week
8.60
Extreme 8.6
9.06
1 month
8.60
Extreme 8.6
9.90
Current year
6.40
Extreme 6.4
9.90
1 year
4.50
Extreme 4.5
9.90
3 years
4.50
Extreme 4.5
14.40
5 years
4.50
Extreme 4.5
14.40
10 years
4.50
Extreme 4.5
14.40
More quotes

Managers and Directors - MaaT Pharma

Managers TitleAgeSince
Hervé Affagard FOU
 Founder - 31/12/13
Siân Crouzet DFI
 Director of Finance/CFO - 31/12/15
Emilie Plantamura CTO
 Chief Tech/Sci/R&D Officer - 28/02/22
Members of the board TitleAgeSince
Isabelle de Cremoux BRD
 Director/Board Member 54 31/12/13
Claude Bertrand BRD
 Director/Board Member 61 15/07/20
Muriel Prudent BRD
 Director/Board Member - -
More insiders

Quotes

Date Price Change Volume
26/04/24 9.06 0.00% 174
25/04/24 9.06 +2.95% 684
24/04/24 8.8 +0.69% 218
23/04/24 8.74 -0.91% 358
22/04/24 8.82 +1.15% 1,965

Real-time Euronext Paris, April 26, 2024 at 01:05 pm

More quotes

Company Profile

MaaT Pharma is specialized in the research and development of microbiome biotherapies for use in the treatment of solid cancer tumors. The company has a portfolio of 2 products in clinical development, including 1 in Phase III (MaaT013 for the treatment of acute graft-versus-host disease) and 1 in Phase IIb (MaaT033 for the prevention of complications of allogeneic hematopoietic stem cell transplantation), and 1 product in preclinical development (MaaT03X for the improvement of the response to immune checkpoint inhibitors in various types of solid tumors).
Sector
Biotechnology & Medical Research
Calendar
13/05/2024 - Q1 2024 Sales and Revenue Release
More about the company

Income Statement Evolution

More financial data

Ratings for MaaT Pharma

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
9.06 EUR
Average target price
15.5 EUR
Spread / Average Target
+71.08%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MAAT PHARMA Stock MaaT Pharma
+29.80% 112M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MAAT Stock